1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. FUSN PHAR
  6. News
  7. Summary
    FUSN   CA36118A1003

FUSN PHAR

(FUSN)
  Report
Delayed Nasdaq  -  03:59 2022-07-01 pm EDT
2.530 USD   +1.61%
06/23SECTOR UPDATE : Health Care Stocks Lead Thursday Markets Recovery
MT
06/23SECTOR UPDATE : Health Care Stocks Again Outpacing Other Sectors to the Upside
MT
06/23SECTOR UPDATE : Health Care Stocks Edge Higher Pre-Bell Thursday
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Fusion Pharmaceuticals to Present at the Guggenheim Securities Radiopharmaceuticals Day

05/11/2022 | 04:46pm EDT

HAMILTON, ON and BOSTON, May 11, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in a fireside chat at the Guggenheim Securities Radiopharmaceuticals Day in New York, New York on Tuesday, May 17, 2022 at 3:00 p.m. ET. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D.

A live webcast of the event will be available on the "Events and Presentations" page in the "Investors & Media" section of the Company's website at https://ir.fusionpharma.com/events-webcasts. A replay of the webcast will be archived on the Company's website for 60 days following the presentation.  

About Fusion

Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434 targeting insulin-like growth factor 1 receptor, is currently in a Phase 1 clinical trial. The pipeline includes FPI-1966, targeting the fibroblast growth factor receptor 3 (FGFR3), advancing to a Phase 1 study following the recent investigational new drug (IND) clearance; and FPI-2059, a small molecule targeting neurotensin receptor 1 (NTSR1). In addition to a robust proprietary pipeline, Fusion has a collaboration with AstraZeneca to jointly develop novel targeted alpha therapies (TATs) and combination programs between Fusion's TATs and AstraZeneca's DNA Damage Repair Inhibitors (DDRis) and immuno-oncology agents. Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with solid tumors expressing IGF-1R. Fusion and Hamilton, Ontario-based McMaster University are building a current Good Manufacturing Practice (GMP) compliant radiopharmaceutical manufacturing facility designed to support manufacturing of the Company's growing pipeline of TATs.

For further information: Amanda Cray, Senior Director of Investor Relations & Corporate Communications, 617-967-0207, cray@fusionpharma.com

Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-present-at-the-guggenheim-securities-radiopharmaceuticals-day-301545338.html

SOURCE Fusion Pharmaceuticals Inc.


© PRNewswire 2022
All news about FUSN PHAR
06/23SECTOR UPDATE : Health Care Stocks Lead Thursday Markets Recovery
MT
06/23SECTOR UPDATE : Health Care Stocks Again Outpacing Other Sectors to the Upside
MT
06/23SECTOR UPDATE : Health Care Stocks Edge Higher Pre-Bell Thursday
MT
06/23Fusion Pharmaceuticals Receives FDA Clearance for Investigational New Drug Application ..
MT
06/23Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-2059, an Investigational ..
AQ
06/23Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-2059, an Investigational ..
CI
06/21FUSION PHARMACEUTICALS INC. : Submission of Matters to a Vote of Security Holders (form 8-..
AQ
06/14Fusion Pharmaceuticals Presents Imaging Data from Cold Antibody Sub-Study in the Phase ..
PR
06/14Fusion Pharmaceuticals Presents Imaging Data from Cold Antibody Sub-Study in the Phase ..
CI
06/10Fusion Pharmaceuticals to Invest $5 Million in Niowave to Ensure Supply of Actinium-225
MT
More news
Analyst Recommendations on FUSN PHAR
More recommendations